All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA accepts supplemental new drug application for selinexor as a treatment for R/R DLBCL
On February 19, 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application (sNDA) filing for selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, who have received ≥ 2 prior therapies. Selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound that selectively binds and inhibits the nuclear export protein exportin 1 (XPO1).1
Selinexor has previously received both orphan drug and fast track designations from the FDA for the treatment of patients with relapsed or refractory DLBCL.2 This was based on the results from the SADAL study (NCT02227251), click here to watch John Kuruvilla discuss it.
Selinexor is approved for the treatment of relapsed and refractory multiple myeloma, and there are ongoing trials for liposarcoma and endometrial cancer.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?